bezuclastinib   Click here for help

GtoPdb Ligand ID: 11868

Synonyms: CGT-9486 | CGT9486 | PLX-9486 | PLX9486
PDB Ligand
Compound class: Synthetic organic
Comment: Bezuclastinib (CGT9486; formerly PLX-9486) is a KIT inhibitor that was designed for anti-tumour potential, particularly for tumours that carry KIT mutations that confer resistance to imatinib [1]. It has limited ability to cross the blood-brain-barrier, so is expected to have a low risk of central nervous system toxicity.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 4
Topological polar surface area 86.46
Molecular weight 331.14
XLogP 4.11
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C(c1n[nH]c(c1C)C)Nc1cnc2c(c1)cc([nH]2)c1ccccc1
Isomeric SMILES Cc1c([nH]nc1C(=O)Nc1cnc2c(c1)cc([nH]2)c1ccccc1)C
InChI InChI=1S/C19H17N5O/c1-11-12(2)23-24-17(11)19(25)21-15-8-14-9-16(22-18(14)20-10-15)13-6-4-3-5-7-13/h3-10H,1-2H3,(H,20,22)(H,21,25)(H,23,24)
InChI Key NVSHVYGIYPBTEZ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Cogent Biosciences have advanced bezuclastinib (= CGT9486) to clinical studies for advanced mastocytosis/mast cell leukemia and advanced/metastatic gastrointestinal stromal tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05208047 (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors Phase 3 Interventional Cogent Biosciences, Inc.
NCT05186753 (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Phase 2 Interventional Cogent Biosciences, Inc.
NCT04996875 (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis Phase 2 Interventional Cogent Biosciences, Inc.